{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:06:11Z","timestamp":1793318771622,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["19K07412"],"award-info":[{"award-number":["19K07412"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s12022-020-09652-z","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T13:17:25Z","timestamp":1604323045000},"page":"359-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Loss of 5-Hydroxymethylcytosine is an Epigenetic Hallmark of Thyroid Carcinomas with TERT Promoter Mutations"],"prefix":"10.1007","volume":"31","author":[{"given":"Naoki","family":"Oishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy Gia","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"9652_CR1","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C (2016) Thyroid cancer. Lancet 388:2783\u20132795. https:\/\/doi.org\/10.1016\/S0140-6736(16)30172-6","journal-title":"Lancet"},{"key":"9652_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"FW Huang","year":"2013","unstructured":"Huang FW, Hodis E, Xu MJ, et al (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957\u20139.\u00a0https:\/\/doi.org\/10.1126\/science.1229259","journal-title":"Science"},{"key":"9652_CR3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1230062","volume":"339","author":"S Horn","year":"2013","unstructured":"Horn S, Figl A, Rachakonda PS, et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959\u201361.\u00a0https:\/\/doi.org\/10.1126\/science.1230062","journal-title":"Science"},{"key":"9652_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1089\/thy.2018.031","volume":"29","author":"M Bullock","year":"2019","unstructured":"Bullock M, Lim G, Zhu Y, et al (2019) ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer. Thyroid 29:1623\u20131633.\u00a0https:\/\/doi.org\/10.1089\/thy.2018.0314","journal-title":"Thyroid"},{"key":"9652_CR5","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1158\/2159-8290.CD-16-0177","volume":"6","author":"SC Ak\u0131nc\u0131lar","year":"2016","unstructured":"Ak\u0131nc\u0131lar SC, Khattar E, Boon PLS, et al (2016) Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation. Cancer Discov 6:1276\u20131291.\u00a0https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0177","journal-title":"Cancer Discov"},{"key":"9652_CR6","doi-asserted-by":"publisher","first-page":"E754","DOI":"10.1210\/jc.2013-3734","volume":"99","author":"M Melo","year":"2014","unstructured":"Melo M, da Rocha AG, Vinagre J, et al (2014) TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. J Clin Endocrinol Metab 99:E754\u2013E765.\u00a0https:\/\/doi.org\/10.1210\/jc.2013-3734","journal-title":"J Clin Endocrinol Metab"},{"key":"9652_CR7","doi-asserted-by":"publisher","first-page":"101042831771391","DOI":"10.1177\/1010428317713913","volume":"39","author":"HG Vuong","year":"2017","unstructured":"Vuong HG, Altibi AM, Duong UN, et al (2017) Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations\u2014a meta-analysis. Tumor Biol 39:101042831771391. https:\/\/doi.org\/10.1177\/1010428317713913","journal-title":"Tumor Biol"},{"key":"9652_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12022-017-9470-y","volume":"28","author":"N Oishi","year":"2017","unstructured":"Oishi N, Kondo T, Nakazawa T, et al (2017) Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan. Endocr Pathol 28:103\u2013111. https:\/\/doi.org\/10.1007\/s12022-017-9470-y","journal-title":"Endocr Pathol"},{"key":"9652_CR9","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/ERC-15-0533","volume":"23","author":"R Liu","year":"2016","unstructured":"Liu R, Xing M (2016) TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 23:R143-55. https:\/\/doi.org\/10.1530\/ERC-15-0533","journal-title":"Endocr Relat Cancer"},{"key":"9652_CR10","doi-asserted-by":"publisher","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","volume":"98","author":"I Landa","year":"2013","unstructured":"Landa I, Ganly I, Chan T, et al (2013) Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease. J Clin Endocrinol Metab 98:E1562\u2013E1566. https:\/\/doi.org\/10.1210\/jc.2013-2383","journal-title":"J Clin Endocrinol Metab"},{"key":"9652_CR11","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/modpathol.2017.75","volume":"30","author":"N Oishi","year":"2017","unstructured":"Oishi N, Kondo T, Ebina A, et al (2017) Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation. Mod Pathol 30:1527\u20131537. https:\/\/doi.org\/10.1038\/modpathol.2017.75","journal-title":"Mod Pathol"},{"key":"9652_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676\u201390. https:\/\/doi.org\/10.1016\/j.cell.2014.09.050","journal-title":"Cell"},{"key":"9652_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/labinvest.2009.50","volume":"89","author":"T Kondo","year":"2009","unstructured":"Kondo T, Nakazawa T, Ma D, et al (2009) Epigenetic silencing of TTF-1\/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Investig 89:791\u2013799. https:\/\/doi.org\/10.1038\/labinvest.2009.50","journal-title":"Lab Investig"},{"key":"9652_CR14","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.cell.2012.07.033","volume":"150","author":"CG Lian","year":"2012","unstructured":"Lian CG, Xu Y, Ceol C, et al (2012) Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150:1135\u201346. https:\/\/doi.org\/10.1016\/j.cell.2012.07.033","journal-title":"Cell"},{"key":"9652_CR15","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1182\/blood-2010-12-324707","volume":"118","author":"E Pronier","year":"2011","unstructured":"Pronier E, Almire C, Mokrani H, et al (2011) Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 118:2551\u20135. https:\/\/doi.org\/10.1182\/blood-2010-12-324707","journal-title":"Blood"},{"key":"9652_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nature09586","volume":"468","author":"M Ko","year":"2010","unstructured":"Ko M, Huang Y, Jankowska AM, et al (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:839\u201343. https:\/\/doi.org\/10.1038\/nature09586","journal-title":"Nature"},{"key":"9652_CR17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/ijc.27429","volume":"131","author":"TFJ Kraus","year":"2012","unstructured":"Kraus TFJ, Globisch D, Wagner M, et al (2012) Low values of 5-hydroxymethylcytosine (5hmC), the \u201csixth base,\u201d are associated with anaplasia in human brain tumors. Int J cancer 131:1577\u201390. https:\/\/doi.org\/10.1002\/ijc.27429","journal-title":"Int J cancer"},{"key":"9652_CR18","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.3892\/ol.2019.10531","volume":"18","author":"M Tong","year":"2019","unstructured":"Tong M, Gao S, Qi W, et al (2019) 5\u2011Hydroxymethylcytosine as a potential epigenetic biomarker in papillary thyroid carcinoma. Oncol Lett 18:2304\u20132309. https:\/\/doi.org\/10.3892\/ol.2019.10531","journal-title":"Oncol Lett"},{"key":"9652_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","volume":"3","author":"R Liu","year":"2017","unstructured":"Liu R, Bishop J, Zhu G, et al (2017) Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer. JAMA Oncol 3:202. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3288","journal-title":"JAMA Oncol"},{"key":"9652_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12022-018-9551-6","volume":"29","author":"JO Paulsson","year":"2018","unstructured":"Paulsson JO, Olander A, Haglund F, et al (2018) TERT Immunohistochemistry Is a Poor Predictor of TERT Promoter Mutations and Gene Expression in Follicular Thyroid Carcinoma. Endocr Pathol 29:380\u2013383. https:\/\/doi.org\/10.1007\/s12022-018-9551-6","journal-title":"Endocr Pathol"},{"key":"9652_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/cyt.12719","volume":"30","author":"X Zhu","year":"2019","unstructured":"Zhu X, Dresser K, Chen BJ (2019) Loss of 5\u2010hydroxymethylcytosine immunohistochemical expression is a useful diagnostic aid for distinguishing hepatocellular carcinoma in cytology fine needle aspiration specimens. Cytopathology 30:492\u2013498. https:\/\/doi.org\/10.1111\/cyt.12719","journal-title":"Cytopathology"},{"key":"9652_CR22","doi-asserted-by":"publisher","first-page":"L9","DOI":"10.1530\/ERC-15-0121","volume":"22","author":"F Haglund","year":"2015","unstructured":"Haglund F, Juhlin CC, Brown T, et al (2015) TERT promoter mutations are rare in parathyroid tumors. Endocr Relat Cancer 22:L9\u2013L11. https:\/\/doi.org\/10.1530\/ERC-15-0121","journal-title":"Endocr Relat Cancer"},{"key":"9652_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13148-016-0197-2","volume":"8","author":"E Barazeghi","year":"2016","unstructured":"Barazeghi E, Gill AJ, Sidhu S, et al (2016) 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma. Clin Epigenetics 8:31. https:\/\/doi.org\/10.1186\/s13148-016-0197-2","journal-title":"Clin Epigenetics"},{"key":"9652_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bbcan.2015.01.001","volume":"1855","author":"LI Kroeze","year":"2015","unstructured":"Kroeze LI, van der Reijden BA, Jansen JH (2015) 5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer. Biochim Biophys Acta - Rev Cancer 1855:144\u2013154. https:\/\/doi.org\/10.1016\/j.bbcan.2015.01.001","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"key":"9652_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1756-8935-6-10","volume":"6","author":"GP Pfeifer","year":"2013","unstructured":"Pfeifer GP, Kadam S, Jin S-G (2013) 5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics Chromatin 6:10. https:\/\/doi.org\/10.1186\/1756-8935-6-10","journal-title":"Epigenetics Chromatin"},{"key":"9652_CR26","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","volume":"120","author":"F Lemonnier","year":"2012","unstructured":"Lemonnier F, Couronne L, Parrens M, et al (2012) Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH -like features and adverse clinical parameters. Blood 120:1466\u20131470. https:\/\/doi.org\/10.1182\/blood-2012-02-408542","journal-title":"Blood"},{"key":"9652_CR27","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.3324\/haematol.2017.167973","volume":"103","author":"F Lemonnier","year":"2018","unstructured":"Lemonnier F, Poullot E, Dupuy A, et al (2018) Loss of 5-hydroxymethylcytosine is a frequent event in peripheral T-cell lymphomas. Haematologica 103:e115\u2013e118. https:\/\/doi.org\/10.3324\/haematol.2017.167973","journal-title":"Haematologica"},{"key":"9652_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, et al (2010) Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell 18:553\u2013567. https:\/\/doi.org\/10.1016\/j.ccr.2010.11.015","journal-title":"Cancer Cell"},{"key":"9652_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, et al (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739\u2013744. https:\/\/doi.org\/10.1038\/nature08617","journal-title":"Nature"},{"key":"9652_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc1111708","volume":"366","author":"L Couronn\u00e9","year":"2012","unstructured":"Couronn\u00e9 L, Bastard C, Bernard OA (2012) TET2 and DNMT3A Mutations in Human T-Cell Lymphoma. N Engl J Med 366:95\u201396. https:\/\/doi.org\/10.1056\/NEJMc1111708","journal-title":"N Engl J Med"},{"key":"9652_CR31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bbrc.2010.02.095","volume":"393","author":"AK Murugan","year":"2010","unstructured":"Murugan AK, Bojdani E, Xing M (2010) Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun 393:555\u2013559. https:\/\/doi.org\/10.1016\/j.bbrc.2010.02.095","journal-title":"Biochem Biophys Res Commun"},{"key":"9652_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/EJE-10-0473","volume":"163","author":"JP Hemerly","year":"2010","unstructured":"Hemerly JP, Bastos AU, Cerutti JM (2010) Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol 163:747\u2013755. https:\/\/doi.org\/10.1530\/EJE-10-0473","journal-title":"Eur J Endocrinol"},{"key":"9652_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s13277-010-0125-6","volume":"32","author":"D Rakheja","year":"2011","unstructured":"Rakheja D, Boriack RL, Mitui M, et al (2011) Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate. Tumor Biol 32:325\u2013333. https:\/\/doi.org\/10.1007\/s13277-010-0125-6","journal-title":"Tumor Biol"},{"key":"9652_CR34","doi-asserted-by":"publisher","unstructured":"Shenoy N, Creagan E, Witzig T, Levine M (2018) Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly. Cancer Cell 1\u20137. https:\/\/doi.org\/10.1016\/j.ccell.2018.07.014","DOI":"10.1016\/j.ccell.2018.07.014"},{"key":"9652_CR35","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1172\/JCI98747","volume":"130","author":"N Shenoy","year":"2019","unstructured":"Shenoy N, Bhagat TD, Cheville J, et al (2019) Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. J Clin Invest 130:1612\u20131625. https:\/\/doi.org\/10.1172\/JCI98747","journal-title":"J Clin Invest"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-020-09652-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-020-09652-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-020-09652-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T04:47:50Z","timestamp":1634273270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-020-09652-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9652"],"URL":"https:\/\/doi.org\/10.1007\/s12022-020-09652-z","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"25 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Approved by the Institutional Review Board of the University of Yamanashi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Approved with the use of an opt-out methodology based on the low risk to the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}